Uncategorized

Data Integrity Guidance

Data integrity is increasingly an area of focus during regulatory inspections across the GXP world and has been the subject of several guidance documents from the FDA, MHRA, and PIC/S. Review of inspectional observations suggests the industry is still struggling to...

Preparing for Your FDA Inspection

At some point on your journey to an approved drug, biologic, or medical device, you (and any contract organizations you’ve hired to help you with nonclinical, GLP, and clinical studies as well as manufacturing) will be subject to inspection by the regulatory...

Background Research for Your IND/NDA/BLA/Market Application

When doing your background work in preparation for a new or updated submission, it can be helpful to understand the structure, personnel and process in the FDA offices with whom you may be working. There are a number of ways you can gather this information, including...

Where Did Former FDA Commissioner Scott Gottlieb Go?

Regular readers will recall my post in March about the departure of FDA Commissioner Scott Gottlieb. He returned to his previous company, venture capital firm New Enterprise Associates Inc, as a Special Partner on their healthcare investment team. He’s also now a...

War Games as a Strategy Tool

I just read an article in Life Science Leader about the use of war games as a strategy tool. This is not a new concept; rather, it’s just a differently structured and more formal way to think more deeply in a strategic mode with a group of up to 40 participants. For...

How Are Citizen Petitions Used?

In my last post, I reviewed the new guidance on the processes available to resolve disagreements arising from official actions or decisions made by members of CDRH. One of those processes is citizen petitions, and because I was interested in how these were used, I...